[
  {
    "ts": "2025-07-30T20:05:00+00:00",
    "headline": "Sage Therapeutics Announces Second Quarter 2025 Financial Results",
    "summary": "CAMBRIDGE, Mass., July 30, 2025--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the second quarter ended June 30, 2025.",
    "url": "https://finance.yahoo.com/news/sage-therapeutics-announces-second-quarter-200500788.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "4466612f-68d6-3c15-af57-6f99952f7a27",
      "content": {
        "id": "4466612f-68d6-3c15-af57-6f99952f7a27",
        "contentType": "STORY",
        "title": "Sage Therapeutics Announces Second Quarter 2025 Financial Results",
        "description": "",
        "summary": "CAMBRIDGE, Mass., July 30, 2025--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the second quarter ended June 30, 2025.",
        "pubDate": "2025-07-30T20:05:00Z",
        "displayTime": "2025-07-30T20:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/64e07e957816d473edd8d4472ff95b0e",
          "originalWidth": 4400,
          "originalHeight": 1387,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DX4VcXNOH8nvfPJJ9yyLmQ--~B/aD0xMzg3O3c9NDQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/64e07e957816d473edd8d4472ff95b0e.cf.webp",
              "width": 4400,
              "height": 1387,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aG9REnFRx2YhxsDetq79wA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/64e07e957816d473edd8d4472ff95b0e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sage-therapeutics-announces-second-quarter-200500788.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sage-therapeutics-announces-second-quarter-200500788.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SUPN"
            },
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "SAGE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-30T15:00:00+00:00",
    "headline": "Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025",
    "summary": "TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI®), an anti-Aβ protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, C",
    "url": "https://finance.yahoo.com/news/two-real-world-study-leqembi-150000490.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "acadc189-ca21-39b6-8cb0-44b2017531f4",
      "content": {
        "id": "acadc189-ca21-39b6-8cb0-44b2017531f4",
        "contentType": "STORY",
        "title": "Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025",
        "description": "",
        "summary": "TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI®), an anti-Aβ protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, C",
        "pubDate": "2025-07-30T15:00:00Z",
        "displayTime": "2025-07-30T15:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d",
          "originalWidth": 865,
          "originalHeight": 290,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IDD9DHtEaM8wc.4J0e2kkA--~B/aD0yOTA7dz04NjU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 865,
              "height": 290,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iODOrgJZ_MV95T9B.jt0vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/two-real-world-study-leqembi-150000490.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/two-real-world-study-leqembi-150000490.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "4523.T"
            },
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-30T13:15:02+00:00",
    "headline": "Biogen (BIIB) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures",
    "summary": "Besides Wall Street's top-and-bottom-line estimates for Biogen (BIIB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.",
    "url": "https://finance.yahoo.com/news/biogen-biib-q2-earnings-horizon-131502628.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "c0194e78-f183-3db0-b702-c7b783b0fb9f",
      "content": {
        "id": "c0194e78-f183-3db0-b702-c7b783b0fb9f",
        "contentType": "STORY",
        "title": "Biogen (BIIB) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures",
        "description": "",
        "summary": "Besides Wall Street's top-and-bottom-line estimates for Biogen (BIIB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.",
        "pubDate": "2025-07-30T13:15:02Z",
        "displayTime": "2025-07-30T13:15:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/03fca48475577988aa4e0db94f484b4e",
          "originalWidth": 900,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9.bMA28djqdXWkJ0xgkrvA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/03fca48475577988aa4e0db94f484b4e.cf.webp",
              "width": 900,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yGQaN1QLRXutAaqBqcTUKw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/03fca48475577988aa4e0db94f484b4e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogen-biib-q2-earnings-horizon-131502628.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-biib-q2-earnings-horizon-131502628.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-30T13:00:00+00:00",
    "headline": "New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease",
    "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that results on investigational maintenance therapy with subcutaneous autoinjector (SC-AI) of lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (Aβ) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Confere",
    "url": "https://finance.yahoo.com/news/data-presented-aaic-demonstrates-investigational-130000675.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "b93aabf2-4269-3561-ad8b-bf92748aaa09",
      "content": {
        "id": "b93aabf2-4269-3561-ad8b-bf92748aaa09",
        "contentType": "STORY",
        "title": "New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease",
        "description": "",
        "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that results on investigational maintenance therapy with subcutaneous autoinjector (SC-AI) of lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (Aβ) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Confere",
        "pubDate": "2025-07-30T13:00:00Z",
        "displayTime": "2025-07-30T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/6c4c3cb7449b0e391efe5ba776c6ca8c",
          "originalWidth": 400,
          "originalHeight": 130,
          "caption": "Image of transition from initial therapy to SC-AI maintenance therapy",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/n5SpwVyiKFMzGs2br_Iv_w--~B/aD0xMzA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/6c4c3cb7449b0e391efe5ba776c6ca8c.cf.webp",
              "width": 400,
              "height": 130,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6e4LvXFSSndxXcQOgJcZNg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/6c4c3cb7449b0e391efe5ba776c6ca8c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/data-presented-aaic-demonstrates-investigational-130000675.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/data-presented-aaic-demonstrates-investigational-130000675.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ESAIY"
            },
            {
              "symbol": "ESALF"
            },
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "4523.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-30T12:07:00+00:00",
    "headline": "Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC",
    "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that the latest findings demonstrating the benefits of continuous treatment with lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (Aβ) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference (AAIC) 20",
    "url": "https://finance.yahoo.com/news/early-alzheimers-patients-continue-benefit-120700034.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "67200861-956e-3657-9fea-2c7747773777",
      "content": {
        "id": "67200861-956e-3657-9fea-2c7747773777",
        "contentType": "STORY",
        "title": "Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC",
        "description": "",
        "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that the latest findings demonstrating the benefits of continuous treatment with lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (Aβ) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference (AAIC) 20",
        "pubDate": "2025-07-30T12:07:00Z",
        "displayTime": "2025-07-30T12:07:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/e4f21722f6516622b1d20bdb2e7ebf2d",
          "originalWidth": 400,
          "originalHeight": 270,
          "caption": "(PRNewsfoto/Eisai Inc.)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IPwq.QXfihaxB1GcLllLgg--~B/aD0yNzA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/e4f21722f6516622b1d20bdb2e7ebf2d.cf.webp",
              "width": 400,
              "height": 270,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/r5ptU2ZctPEBo4lbeTgQDg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/e4f21722f6516622b1d20bdb2e7ebf2d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/early-alzheimers-patients-continue-benefit-120700034.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/early-alzheimers-patients-continue-benefit-120700034.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "4523.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-30T09:41:02+00:00",
    "headline": "Eli Lilly eyes SoC status as Jaypirca proves superior to Imbruvica in CLL/SLL",
    "summary": "Jaypirca met its non-inferiority primary endpoint, trumping Imbruvica in patient overall response rate (ORR).",
    "url": "https://www.clinicaltrialsarena.com/news/eli-lilly-jaypirca-phase-iii-results/",
    "source": "Clinical Trials Arena",
    "provider": "yfinance",
    "raw": {
      "id": "df462f88-f0ba-3949-b1b2-0aaf54405a26",
      "content": {
        "id": "df462f88-f0ba-3949-b1b2-0aaf54405a26",
        "contentType": "STORY",
        "title": "Eli Lilly eyes SoC status as Jaypirca proves superior to Imbruvica in CLL/SLL",
        "description": "",
        "summary": "Jaypirca met its non-inferiority primary endpoint, trumping Imbruvica in patient overall response rate (ORR).",
        "pubDate": "2025-07-30T09:41:02Z",
        "displayTime": "2025-07-30T09:41:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/clinical_trials_arena_396/d92cf945f182b7f2a80fbb9e41f98787",
          "originalWidth": 2121,
          "originalHeight": 1414,
          "caption": "Eli Lilly's Jaypirca elicited a better ORR than the current SoC",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hXqp960gwheQOcbro7Xhcg--~B/aD0xNDE0O3c9MjEyMTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/clinical_trials_arena_396/d92cf945f182b7f2a80fbb9e41f98787.cf.webp",
              "width": 2121,
              "height": 1414,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/n5pDa5cwc57ewdDwdSjbKA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/clinical_trials_arena_396/d92cf945f182b7f2a80fbb9e41f98787.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Clinical Trials Arena",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.clinicaltrialsarena.com/news/eli-lilly-jaypirca-phase-iii-results/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-eyes-soc-status-094102181.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-30T03:06:53+00:00",
    "headline": "Biogen Earnings: What To Look For From BIIB",
    "summary": "Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Thursday morning. Here’s what you need to know.",
    "url": "https://finance.yahoo.com/news/biogen-earnings-look-biib-030653715.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "e7372737-6357-314a-b96c-07e5842eb5d9",
      "content": {
        "id": "e7372737-6357-314a-b96c-07e5842eb5d9",
        "contentType": "STORY",
        "title": "Biogen Earnings: What To Look For From BIIB",
        "description": "",
        "summary": "Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Thursday morning. Here’s what you need to know.",
        "pubDate": "2025-07-30T03:06:53Z",
        "displayTime": "2025-07-30T03:06:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/3e9471166a0d4ee8c41ab9eef8ac261c",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "BIIB Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RI16PwyrPkPhFQpSFVHcpw--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/3e9471166a0d4ee8c41ab9eef8ac261c.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IR.mhpWSH09RyIH1vck_EQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/3e9471166a0d4ee8c41ab9eef8ac261c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogen-earnings-look-biib-030653715.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-earnings-look-biib-030653715.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]